Dr. Ray Goodrich talks about his new clinical trial that aims to use whole, light-inactivated tumor cells for immunotherapy

MIP professor Raymond Goodrich has developed a cancer immunotherapy that uses a patient’s own tumor cells to train the immune system

MIP Professor Raymond Goodrich is leading a team of researchers at Colorado State University that have developed an innovative new cancer immunotherapy and will begin enrolling ovarian cancer patients by the end of this year to test the treatment in the first phase of a human clinical trial.

MIP Professor Ray Goodrich and his team have developed a new personalized immunotherapy for ovarian cancer patients.

CSU Professor Ray Goodrich won the award for the development and implementation of pathogen-reduction technology.

CSU Professor Ray Goodrich and his lab are developing a new immunotherapy approach to treat cancer.

Dr. Ray Goodrich is a recipient of a grant from OEDIT to develop a device for treating blood products to prevent the transfusion of transmitted diseases.

Researchers at Colorado State University with Ray Goodrich are working on four COVID-19 vaccine candidates, one of which is nearing human clinical trials.

Ray Goodrich partners with Okoth to create an inactivated ASF vaccine that maintains the structure of the virus as close to the natural pathogen as possible.